Replies to post #160834 on Biotech Values

[mcbio]

PTLA—Depending on the post-IPO valuation, I might be tempted. If the FXa reverser works well, I could see PFE (or BMY) buying the whole company. (An acquirer would shut down the betrixaban program, of course.)

Is ~$500M (#msg-87681951 ) too steep?